CLINICAL_TRIALS
trial_result
· 2011-09-12
Clinical Trial Update: CDP323 Biomarker Study [Phase 1, Phase 2]
Summary
This document reports the completion of a Phase 1/Phase 2 biomarker study of CDP323 in relapsing multiple sclerosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Relapsing Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED